CovidFranceV1, Main, Exploration, bibRecord, 000543

Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.

Identifieur interne : 000543 ( Main/Exploration ); précédent : 000542; suivant : 000544

Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.

Auteurs : Yüksel Ürün [Turquie] ; Syed A. Hussain [Royaume-Uni] ; Ziad Bakouny [États-Unis] ; Daniel Castellano [Espagne] ; Saadettin K L Çkap [Turquie] ; Gilberto Morgan [Suède] ; Rana R. Mckay [États-Unis] ; Kevin Pels [États-Unis] ; Andrew Schmidt [États-Unis] ; Deborah B. Doroshow [États-Unis] ; Fábio Schütz [Brésil] ; Laurence Albiges [France] ; Gilberto Lopes [États-Unis] ; James W F. Catto [Royaume-Uni] ; Solange Peters [Suisse] ; Toni K. Choueiri [États-Unis]

Source :

JCO global oncology [ 2687-8941 ] ; 2020.

RBID : pubmed:32755479

Descripteurs français

English descriptors

KwdEn :
- Adult (MeSH), Aged (MeSH), Betacoronavirus (pathogenicity), Clinical Decision-Making (MeSH), Coronavirus Infections (epidemiology), Coronavirus Infections (prevention & control), Coronavirus Infections (transmission), Coronavirus Infections (virology), Female (MeSH), Humans (MeSH), Infection Control (methods), Infection Control (standards), Infection Control (statistics & numerical data), Infectious Disease Transmission, Patient-to-Professional (prevention & control), Infectious Disease Transmission, Professional-to-Patient (prevention & control), Male (MeSH), Medical Oncology (methods), Medical Oncology (standards), Medical Oncology (statistics & numerical data), Middle Aged (MeSH), Neoplasms (diagnosis), Neoplasms (therapy), Oncologists (statistics & numerical data), Pandemics (prevention & control), Personal Protective Equipment (standards), Personal Protective Equipment (statistics & numerical data), Pneumonia, Viral (epidemiology), Pneumonia, Viral (prevention & control), Pneumonia, Viral (transmission), Pneumonia, Viral (virology), Practice Patterns, Physicians' (standards), Practice Patterns, Physicians' (statistics & numerical data), Surveys and Questionnaires (statistics & numerical data), Telemedicine (statistics & numerical data).
MESH :
- diagnosis : Neoplasms.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- methods : Infection Control, Medical Oncology.
- pathogenicity : Betacoronavirus.
- prevention & control : Coronavirus Infections, Infectious Disease Transmission, Patient-to-Professional, Infectious Disease Transmission, Professional-to-Patient, Pandemics, Pneumonia, Viral.
- standards : Infection Control, Medical Oncology, Personal Protective Equipment, Practice Patterns, Physicians'.
- statistics & numerical data : Infection Control, Medical Oncology, Oncologists, Personal Protective Equipment, Practice Patterns, Physicians', Surveys and Questionnaires, Telemedicine.
- therapy : Neoplasms.
- transmission : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Adult, Aged, Clinical Decision-Making, Female, Humans, Male, Middle Aged.

Abstract

PURPOSE

To understand readiness measures taken by oncologists to protect patients and health care workers from the novel coronavirus (COVID-19) and how their clinical decision making was influenced by the pandemic.

METHODS

An online survey was conducted between March 24 and April 29, 2020.

RESULTS

A total of 343 oncologists from 28 countries participated. The median age was 43 years (range, 29-68 years), and the majority were male (62%). At the time of the survey, nearly all participants self-reported an outbreak in their country (99.7%). Personal protective equipment was available to all participants, of which surgical mask was the most common (n = 308; 90%). Telemedicine, in the form of phone or video encounters, was common and implemented by 80% (n = 273). Testing patients with cancer for COVID-19 via reverse transcriptase polymerase chain reaction before systemic treatment was not routinely implemented: 58% reported no routine testing, 39% performed testing in selected patients, and 3% performed systematic testing in all patients. The most significant factors influencing an oncologist's decision making regarding choice of systemic therapy included patient age and comorbidities (81% and 92%, respectively). Although hormonal treatments and tyrosine kinase inhibitors were considered to be relatively safe, cytotoxic chemotherapy and immune therapies were perceived as being less safe or unsafe by participants. The vast majority of participants stated that during the pandemic they would use less chemotherapy, immune checkpoint inhibitors, and steroids. Although treatment in neoadjuvant, adjuvant, and first-line metastatic disease was less affected, most of the participants stated that they would be more hesitant to recommend second- or third-line therapies in metastatic disease.

CONCLUSION

Decision making by oncologists has been significantly influenced by the ongoing COVID-19 pandemic.

DOI: 10.1200/GO.20.00300
PubMed: 32755479

Affiliations:

Brésil, Espagne, France, Royaume-Uni, Suisse, Suède, Turquie, États-Unis
Californie, Canton de Vaud, Communauté de Madrid, Floride, Massachusetts, État de New York, État de São Paulo
Lausanne, Madrid, São Paulo, Villejuif

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000717
to stream Main, to step Curation: 000717

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.</title>
<author><name sortKey="Urun, Yuksel" sort="Urun, Yuksel" uniqKey="Urun Y" first="Yüksel" last="Ürün">Yüksel Ürün</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Medical Oncology, Ankara University School of Medicine, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Ankara University Cancer Research Institute, Ankara, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Ankara University Cancer Research Institute, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hussain, Syed A" sort="Hussain, Syed A" uniqKey="Hussain S" first="Syed A" last="Hussain">Syed A. Hussain</name>
<affiliation wicri:level="1"><nlm:affiliation>Academic Unit of Oncology, University of Sheffield, Sheffield, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Academic Unit of Oncology, University of Sheffield, Sheffield</wicri:regionArea>
<wicri:noRegion>Sheffield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bakouny, Ziad" sort="Bakouny, Ziad" uniqKey="Bakouny Z" first="Ziad" last="Bakouny">Ziad Bakouny</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Castellano, Daniel" sort="Castellano, Daniel" uniqKey="Castellano D" first="Daniel" last="Castellano">Daniel Castellano</name>
<affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="K L Ckap, Saadettin" sort="K L Ckap, Saadettin" uniqKey="K L Ckap S" first="Saadettin" last="K L Çkap">Saadettin K L Çkap</name>
<affiliation wicri:level="1"><nlm:affiliation>Hacettepe University Cancer Institute, Ankara, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Hacettepe University Cancer Institute, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morgan, Gilberto" sort="Morgan, Gilberto" uniqKey="Morgan G" first="Gilberto" last="Morgan">Gilberto Morgan</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Radiation Oncology, Skåne University Hospital, Lund, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Medical and Radiation Oncology, Skåne University Hospital, Lund</wicri:regionArea>
<wicri:noRegion>Lund</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mckay, Rana R" sort="Mckay, Rana R" uniqKey="Mckay R" first="Rana R" last="Mckay">Rana R. Mckay</name>
<affiliation wicri:level="2"><nlm:affiliation>Moores Cancer Center, University of California San Diego, La Jolla, CA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Moores Cancer Center, University of California San Diego, La Jolla</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Pels, Kevin" sort="Pels, Kevin" uniqKey="Pels K" first="Kevin" last="Pels">Kevin Pels</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Schmidt, Andrew" sort="Schmidt, Andrew" uniqKey="Schmidt A" first="Andrew" last="Schmidt">Andrew Schmidt</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Doroshow, Deborah B" sort="Doroshow, Deborah B" uniqKey="Doroshow D" first="Deborah B" last="Doroshow">Deborah B. Doroshow</name>
<affiliation wicri:level="2"><nlm:affiliation>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Schutz, Fabio" sort="Schutz, Fabio" uniqKey="Schutz F" first="Fábio" last="Schütz">Fábio Schütz</name>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Oncology Department, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Clinical Oncology Department, BP - A Beneficência Portuguesa de São Paulo, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Albiges, Laurence" sort="Albiges, Laurence" uniqKey="Albiges L" first="Laurence" last="Albiges">Laurence Albiges</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea>
<placeName><settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lopes, Gilberto" sort="Lopes, Gilberto" uniqKey="Lopes G" first="Gilberto" last="Lopes">Gilberto Lopes</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Hematology and Medical Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Division of Hematology and Medical Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Catto, James W F" sort="Catto, James W F" uniqKey="Catto J" first="James W F" last="Catto">James W F. Catto</name>
<affiliation wicri:level="1"><nlm:affiliation>Academic Unit of Oncology, University of Sheffield, Sheffield, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Academic Unit of Oncology, University of Sheffield, Sheffield</wicri:regionArea>
<wicri:noRegion>Sheffield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peters, Solange" sort="Peters, Solange" uniqKey="Peters S" first="Solange" last="Peters">Solange Peters</name>
<affiliation wicri:level="3"><nlm:affiliation>Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne</wicri:regionArea>
<placeName><settlement type="city">Lausanne</settlement>
<region nuts="3" type="region">Canton de Vaud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Choueiri, Toni K" sort="Choueiri, Toni K" uniqKey="Choueiri T" first="Toni K" last="Choueiri">Toni K. Choueiri</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32755479</idno>
<idno type="pmid">32755479</idno>
<idno type="doi">10.1200/GO.20.00300</idno>
<idno type="wicri:Area/Main/Corpus">000717</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000717</idno>
<idno type="wicri:Area/Main/Curation">000717</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000717</idno>
<idno type="wicri:Area/Main/Exploration">000717</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.</title>
<author><name sortKey="Urun, Yuksel" sort="Urun, Yuksel" uniqKey="Urun Y" first="Yüksel" last="Ürün">Yüksel Ürün</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Medical Oncology, Ankara University School of Medicine, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Ankara University Cancer Research Institute, Ankara, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Ankara University Cancer Research Institute, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hussain, Syed A" sort="Hussain, Syed A" uniqKey="Hussain S" first="Syed A" last="Hussain">Syed A. Hussain</name>
<affiliation wicri:level="1"><nlm:affiliation>Academic Unit of Oncology, University of Sheffield, Sheffield, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Academic Unit of Oncology, University of Sheffield, Sheffield</wicri:regionArea>
<wicri:noRegion>Sheffield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bakouny, Ziad" sort="Bakouny, Ziad" uniqKey="Bakouny Z" first="Ziad" last="Bakouny">Ziad Bakouny</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Castellano, Daniel" sort="Castellano, Daniel" uniqKey="Castellano D" first="Daniel" last="Castellano">Daniel Castellano</name>
<affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="K L Ckap, Saadettin" sort="K L Ckap, Saadettin" uniqKey="K L Ckap S" first="Saadettin" last="K L Çkap">Saadettin K L Çkap</name>
<affiliation wicri:level="1"><nlm:affiliation>Hacettepe University Cancer Institute, Ankara, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Hacettepe University Cancer Institute, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morgan, Gilberto" sort="Morgan, Gilberto" uniqKey="Morgan G" first="Gilberto" last="Morgan">Gilberto Morgan</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical and Radiation Oncology, Skåne University Hospital, Lund, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Medical and Radiation Oncology, Skåne University Hospital, Lund</wicri:regionArea>
<wicri:noRegion>Lund</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mckay, Rana R" sort="Mckay, Rana R" uniqKey="Mckay R" first="Rana R" last="Mckay">Rana R. Mckay</name>
<affiliation wicri:level="2"><nlm:affiliation>Moores Cancer Center, University of California San Diego, La Jolla, CA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Moores Cancer Center, University of California San Diego, La Jolla</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Pels, Kevin" sort="Pels, Kevin" uniqKey="Pels K" first="Kevin" last="Pels">Kevin Pels</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Schmidt, Andrew" sort="Schmidt, Andrew" uniqKey="Schmidt A" first="Andrew" last="Schmidt">Andrew Schmidt</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Doroshow, Deborah B" sort="Doroshow, Deborah B" uniqKey="Doroshow D" first="Deborah B" last="Doroshow">Deborah B. Doroshow</name>
<affiliation wicri:level="2"><nlm:affiliation>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Schutz, Fabio" sort="Schutz, Fabio" uniqKey="Schutz F" first="Fábio" last="Schütz">Fábio Schütz</name>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Oncology Department, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Clinical Oncology Department, BP - A Beneficência Portuguesa de São Paulo, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Albiges, Laurence" sort="Albiges, Laurence" uniqKey="Albiges L" first="Laurence" last="Albiges">Laurence Albiges</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea>
<placeName><settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lopes, Gilberto" sort="Lopes, Gilberto" uniqKey="Lopes G" first="Gilberto" last="Lopes">Gilberto Lopes</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Hematology and Medical Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Division of Hematology and Medical Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Catto, James W F" sort="Catto, James W F" uniqKey="Catto J" first="James W F" last="Catto">James W F. Catto</name>
<affiliation wicri:level="1"><nlm:affiliation>Academic Unit of Oncology, University of Sheffield, Sheffield, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Academic Unit of Oncology, University of Sheffield, Sheffield</wicri:regionArea>
<wicri:noRegion>Sheffield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peters, Solange" sort="Peters, Solange" uniqKey="Peters S" first="Solange" last="Peters">Solange Peters</name>
<affiliation wicri:level="3"><nlm:affiliation>Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne</wicri:regionArea>
<placeName><settlement type="city">Lausanne</settlement>
<region nuts="3" type="region">Canton de Vaud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Choueiri, Toni K" sort="Choueiri, Toni K" uniqKey="Choueiri T" first="Toni K" last="Choueiri">Toni K. Choueiri</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">JCO global oncology</title>
<idno type="eISSN">2687-8941</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>Clinical Decision-Making (MeSH)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Coronavirus Infections (transmission)</term>
<term>Coronavirus Infections (virology)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Infection Control (methods)</term>
<term>Infection Control (standards)</term>
<term>Infection Control (statistics & numerical data)</term>
<term>Infectious Disease Transmission, Patient-to-Professional (prevention & control)</term>
<term>Infectious Disease Transmission, Professional-to-Patient (prevention & control)</term>
<term>Male (MeSH)</term>
<term>Medical Oncology (methods)</term>
<term>Medical Oncology (standards)</term>
<term>Medical Oncology (statistics & numerical data)</term>
<term>Middle Aged (MeSH)</term>
<term>Neoplasms (diagnosis)</term>
<term>Neoplasms (therapy)</term>
<term>Oncologists (statistics & numerical data)</term>
<term>Pandemics (prevention & control)</term>
<term>Personal Protective Equipment (standards)</term>
<term>Personal Protective Equipment (statistics & numerical data)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (prevention & control)</term>
<term>Pneumonia, Viral (transmission)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Practice Patterns, Physicians' (standards)</term>
<term>Practice Patterns, Physicians' (statistics & numerical data)</term>
<term>Surveys and Questionnaires (statistics & numerical data)</term>
<term>Telemedicine (statistics & numerical data)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Betacoronavirus (pathogénicité)</term>
<term>Enquêtes et questionnaires (statistiques et données numériques)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (prévention et contrôle)</term>
<term>Infections à coronavirus (transmission)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Mâle (MeSH)</term>
<term>Oncologie médicale (méthodes)</term>
<term>Oncologie médicale (normes)</term>
<term>Oncologie médicale (statistiques et données numériques)</term>
<term>Oncologues (statistiques et données numériques)</term>
<term>Pandémies (prévention et contrôle)</term>
<term>Pneumopathie virale (prévention et contrôle)</term>
<term>Pneumopathie virale (transmission)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Prise de décision clinique (MeSH)</term>
<term>Prévention des infections (méthodes)</term>
<term>Prévention des infections (normes)</term>
<term>Prévention des infections (statistiques et données numériques)</term>
<term>Sujet âgé (MeSH)</term>
<term>Transmission de maladie infectieuse du patient au professionnel de santé (prévention et contrôle)</term>
<term>Transmission de maladie infectieuse du professionnel de santé au patient (prévention et contrôle)</term>
<term>Tumeurs (diagnostic)</term>
<term>Tumeurs (thérapie)</term>
<term>Types de pratiques des médecins (normes)</term>
<term>Types de pratiques des médecins (statistiques et données numériques)</term>
<term>Télémédecine (statistiques et données numériques)</term>
<term>Équipement de protection individuelle (normes)</term>
<term>Équipement de protection individuelle (statistiques et données numériques)</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Infection Control</term>
<term>Medical Oncology</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Oncologie médicale</term>
<term>Prévention des infections</term>
</keywords>
<keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Oncologie médicale</term>
<term>Prévention des infections</term>
<term>Types de pratiques des médecins</term>
<term>Équipement de protection individuelle</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
<term>Infectious Disease Transmission, Patient-to-Professional</term>
<term>Infectious Disease Transmission, Professional-to-Patient</term>
<term>Pandemics</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pandémies</term>
<term>Pneumopathie virale</term>
<term>Transmission de maladie infectieuse du patient au professionnel de santé</term>
<term>Transmission de maladie infectieuse du professionnel de santé au patient</term>
</keywords>
<keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Infection Control</term>
<term>Medical Oncology</term>
<term>Personal Protective Equipment</term>
<term>Practice Patterns, Physicians'</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Infection Control</term>
<term>Medical Oncology</term>
<term>Oncologists</term>
<term>Personal Protective Equipment</term>
<term>Practice Patterns, Physicians'</term>
<term>Surveys and Questionnaires</term>
<term>Telemedicine</term>
</keywords>
<keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Enquêtes et questionnaires</term>
<term>Oncologie médicale</term>
<term>Oncologues</term>
<term>Prévention des infections</term>
<term>Types de pratiques des médecins</term>
<term>Télémédecine</term>
<term>Équipement de protection individuelle</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Clinical Decision-Making</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Prise de décision clinique</term>
<term>Sujet âgé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>PURPOSE</b>
</p>
<p>To understand readiness measures taken by oncologists to protect patients and health care workers from the novel coronavirus (COVID-19) and how their clinical decision making was influenced by the pandemic.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>An online survey was conducted between March 24 and April 29, 2020.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>A total of 343 oncologists from 28 countries participated. The median age was 43 years (range, 29-68 years), and the majority were male (62%). At the time of the survey, nearly all participants self-reported an outbreak in their country (99.7%). Personal protective equipment was available to all participants, of which surgical mask was the most common (n = 308; 90%). Telemedicine, in the form of phone or video encounters, was common and implemented by 80% (n = 273). Testing patients with cancer for COVID-19 via reverse transcriptase polymerase chain reaction before systemic treatment was not routinely implemented: 58% reported no routine testing, 39% performed testing in selected patients, and 3% performed systematic testing in all patients. The most significant factors influencing an oncologist's decision making regarding choice of systemic therapy included patient age and comorbidities (81% and 92%, respectively). Although hormonal treatments and tyrosine kinase inhibitors were considered to be relatively safe, cytotoxic chemotherapy and immune therapies were perceived as being less safe or unsafe by participants. The vast majority of participants stated that during the pandemic they would use less chemotherapy, immune checkpoint inhibitors, and steroids. Although treatment in neoadjuvant, adjuvant, and first-line metastatic disease was less affected, most of the participants stated that they would be more hesitant to recommend second- or third-line therapies in metastatic disease.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>Decision making by oncologists has been significantly influenced by the ongoing COVID-19 pandemic.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32755479</PMID>
<DateCompleted><Year>2020</Year>
<Month>08</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>08</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>6</Volume>
<PubDate><Year>2020</Year>
<Month>08</Month>
</PubDate>
</JournalIssue>
<Title>JCO global oncology</Title>
<ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.</ArticleTitle>
<Pagination><MedlinePgn>1248-1257</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1200/GO.20.00300</ELocationID>
<Abstract><AbstractText Label="PURPOSE">To understand readiness measures taken by oncologists to protect patients and health care workers from the novel coronavirus (COVID-19) and how their clinical decision making was influenced by the pandemic.</AbstractText>
<AbstractText Label="METHODS">An online survey was conducted between March 24 and April 29, 2020.</AbstractText>
<AbstractText Label="RESULTS">A total of 343 oncologists from 28 countries participated. The median age was 43 years (range, 29-68 years), and the majority were male (62%). At the time of the survey, nearly all participants self-reported an outbreak in their country (99.7%). Personal protective equipment was available to all participants, of which surgical mask was the most common (n = 308; 90%). Telemedicine, in the form of phone or video encounters, was common and implemented by 80% (n = 273). Testing patients with cancer for COVID-19 via reverse transcriptase polymerase chain reaction before systemic treatment was not routinely implemented: 58% reported no routine testing, 39% performed testing in selected patients, and 3% performed systematic testing in all patients. The most significant factors influencing an oncologist's decision making regarding choice of systemic therapy included patient age and comorbidities (81% and 92%, respectively). Although hormonal treatments and tyrosine kinase inhibitors were considered to be relatively safe, cytotoxic chemotherapy and immune therapies were perceived as being less safe or unsafe by participants. The vast majority of participants stated that during the pandemic they would use less chemotherapy, immune checkpoint inhibitors, and steroids. Although treatment in neoadjuvant, adjuvant, and first-line metastatic disease was less affected, most of the participants stated that they would be more hesitant to recommend second- or third-line therapies in metastatic disease.</AbstractText>
<AbstractText Label="CONCLUSION">Decision making by oncologists has been significantly influenced by the ongoing COVID-19 pandemic.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ürün</LastName>
<ForeName>Yüksel</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Ankara University Cancer Research Institute, Ankara, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hussain</LastName>
<ForeName>Syed A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo><Affiliation>Academic Unit of Oncology, University of Sheffield, Sheffield, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bakouny</LastName>
<ForeName>Ziad</ForeName>
<Initials>Z</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Castellano</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kılıçkap</LastName>
<ForeName>Saadettin</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Hacettepe University Cancer Institute, Ankara, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Morgan</LastName>
<ForeName>Gilberto</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Medical and Radiation Oncology, Skåne University Hospital, Lund, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mckay</LastName>
<ForeName>Rana R</ForeName>
<Initials>RR</Initials>
<AffiliationInfo><Affiliation>Moores Cancer Center, University of California San Diego, La Jolla, CA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pels</LastName>
<ForeName>Kevin</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schmidt</LastName>
<ForeName>Andrew</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Doroshow</LastName>
<ForeName>Deborah B</ForeName>
<Initials>DB</Initials>
<AffiliationInfo><Affiliation>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schütz</LastName>
<ForeName>Fábio</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Clinical Oncology Department, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Albiges</LastName>
<ForeName>Laurence</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lopes</LastName>
<ForeName>Gilberto</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Division of Hematology and Medical Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Catto</LastName>
<ForeName>James W F</ForeName>
<Initials>JWF</Initials>
<AffiliationInfo><Affiliation>Academic Unit of Oncology, University of Sheffield, Sheffield, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Peters</LastName>
<ForeName>Solange</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Choueiri</LastName>
<ForeName>Toni K</ForeName>
<Initials>TK</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>JCO Glob Oncol</MedlineTA>
<NlmUniqueID>101760170</NlmUniqueID>
<ISSNLinking>2687-8941</ISSNLinking>
</MedlineJournalInfo>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000066491" MajorTopicYN="Y">Clinical Decision-Making</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017053" MajorTopicYN="N">Infection Control</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
<QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017758" MajorTopicYN="N">Infectious Disease Transmission, Patient-to-Professional</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017757" MajorTopicYN="N">Infectious Disease Transmission, Professional-to-Patient</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008495" MajorTopicYN="N">Medical Oncology</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
<QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000072103" MajorTopicYN="N">Oncologists</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000067393" MajorTopicYN="N">Personal Protective Equipment</DescriptorName>
<QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName>
<QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017216" MajorTopicYN="N">Telemedicine</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32755479</ArticleId>
<ArticleId IdType="doi">10.1200/GO.20.00300</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Brésil</li>
<li>Espagne</li>
<li>France</li>
<li>Royaume-Uni</li>
<li>Suisse</li>
<li>Suède</li>
<li>Turquie</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Canton de Vaud</li>
<li>Communauté de Madrid</li>
<li>Floride</li>
<li>Massachusetts</li>
<li>État de New York</li>
<li>État de São Paulo</li>
</region>
<settlement><li>Lausanne</li>
<li>Madrid</li>
<li>São Paulo</li>
<li>Villejuif</li>
</settlement>
</list>
<tree><country name="Turquie"><noRegion><name sortKey="Urun, Yuksel" sort="Urun, Yuksel" uniqKey="Urun Y" first="Yüksel" last="Ürün">Yüksel Ürün</name>
</noRegion>
<name sortKey="K L Ckap, Saadettin" sort="K L Ckap, Saadettin" uniqKey="K L Ckap S" first="Saadettin" last="K L Çkap">Saadettin K L Çkap</name>
<name sortKey="Urun, Yuksel" sort="Urun, Yuksel" uniqKey="Urun Y" first="Yüksel" last="Ürün">Yüksel Ürün</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Hussain, Syed A" sort="Hussain, Syed A" uniqKey="Hussain S" first="Syed A" last="Hussain">Syed A. Hussain</name>
</noRegion>
<name sortKey="Catto, James W F" sort="Catto, James W F" uniqKey="Catto J" first="James W F" last="Catto">James W F. Catto</name>
</country>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Bakouny, Ziad" sort="Bakouny, Ziad" uniqKey="Bakouny Z" first="Ziad" last="Bakouny">Ziad Bakouny</name>
</region>
<name sortKey="Choueiri, Toni K" sort="Choueiri, Toni K" uniqKey="Choueiri T" first="Toni K" last="Choueiri">Toni K. Choueiri</name>
<name sortKey="Doroshow, Deborah B" sort="Doroshow, Deborah B" uniqKey="Doroshow D" first="Deborah B" last="Doroshow">Deborah B. Doroshow</name>
<name sortKey="Lopes, Gilberto" sort="Lopes, Gilberto" uniqKey="Lopes G" first="Gilberto" last="Lopes">Gilberto Lopes</name>
<name sortKey="Mckay, Rana R" sort="Mckay, Rana R" uniqKey="Mckay R" first="Rana R" last="Mckay">Rana R. Mckay</name>
<name sortKey="Pels, Kevin" sort="Pels, Kevin" uniqKey="Pels K" first="Kevin" last="Pels">Kevin Pels</name>
<name sortKey="Schmidt, Andrew" sort="Schmidt, Andrew" uniqKey="Schmidt A" first="Andrew" last="Schmidt">Andrew Schmidt</name>
</country>
<country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Castellano, Daniel" sort="Castellano, Daniel" uniqKey="Castellano D" first="Daniel" last="Castellano">Daniel Castellano</name>
</region>
</country>
<country name="Suède"><noRegion><name sortKey="Morgan, Gilberto" sort="Morgan, Gilberto" uniqKey="Morgan G" first="Gilberto" last="Morgan">Gilberto Morgan</name>
</noRegion>
</country>
<country name="Brésil"><region name="État de São Paulo"><name sortKey="Schutz, Fabio" sort="Schutz, Fabio" uniqKey="Schutz F" first="Fábio" last="Schütz">Fábio Schütz</name>
</region>
</country>
<country name="France"><noRegion><name sortKey="Albiges, Laurence" sort="Albiges, Laurence" uniqKey="Albiges L" first="Laurence" last="Albiges">Laurence Albiges</name>
</noRegion>
</country>
<country name="Suisse"><region name="Canton de Vaud"><name sortKey="Peters, Solange" sort="Peters, Solange" uniqKey="Peters S" first="Solange" last="Peters">Solange Peters</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000543 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000543 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32755479
   |texte=   Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32755479" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidFranceV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 23:31:36 2020. Site generation: Fri Feb 12 22:48:37 2021

	Serveur d'exploration sur la COVID en France
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID en France

Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.

Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki